Aerie Pharmaceuticals to Participate in Three Investor Conferences in November
November 03 2016 - 7:30AM
Business Wire
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage
pharmaceutical company focused on the discovery, development and
commercialization of first-in-class glaucoma therapies, today
announced that company management will present an overview of the
company at the following conferences in November.
- Raymond James Fall Investor Conference
- Attendee: Vicente Anido, Jr., Ph.D.,
Chairman and Chief Executive Officer
- Date: Tuesday, November 15, 2016
- Location: Boston, MA
- Jefferies 2016 London Healthcare
Conference
- Presenter: Richard Rubino, Chief
Financial Officer
- Presentation Date: Wednesday, November
16, 2016
- Presentation Time: 1:20pm G.M.T.
- Location: London, UK
- Stifel Nicolaus 2016 Healthcare
Conference
- Presenter: Vicente Anido, Jr., Ph.D.,
Chairman and Chief Executive Officer
- Presentation Date: Wednesday, November
16, 2016
- Presentation Time: 9:30am E.T.
- Location: New York, NY
The Jefferies 2016 London Healthcare Conference presentation and
Stifel Nicolaus 2016 Healthcare Conference fireside chat discussion
will be webcast live and may be accessed by visiting Aerie's
website at http://investors.aeriepharma.com/. A replay of each
webcast will be available for 10 business days.
About Aerie Pharmaceuticals, Inc.
Aerie is a clinical-stage pharmaceutical company focused on the
discovery, development and commercialization of first-in-class
therapies for the treatment of patients with glaucoma and other
diseases of the eye. Aerie's two lead product candidates are
once-daiIy IOP-lowering therapies with novel mechanisms of action
to treat patients with glaucoma or ocular hypertension. The NDA
filing for Rhopressa™ (netarsudil ophthalmic solution) 0.02%
was originally submitted in the third quarter of 2016 and is
expected to be resubmitted in January 2017. The second product
candidate, Roclatan™ (netarsudil/latanoprost ophthalmic
solution) 0.02%/0.005%, which is a fixed dose combination of
Rhopressa™ and widely prescribed PGA latanoprost,
currently has two Phase 3 registration trials underway, named
Mercury 1 and Mercury 2. If these trials are successful, a
Roclatan™ NDA filing is expected to take place near year-end
2017. Aerie is also focused on the development of additional
product candidates and technologies in ophthalmology.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161103005168/en/
Aerie PharmaceuticalsRichard Rubino,
908-947-3540rrubino@aeriepharma.comorBurns McClellan, Inc., on
behalf of Aerie PharmaceuticalsAmi Bavishi,
212-213-0006abavishi@burnsmc.com
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Apr 2023 to Apr 2024